The Rise of Cash-Pay Cancer Screening: Eve Wellness Expands AI Clinics

SAN FRANCISCO, CA – October 01, 2026 – As Breast Cancer Awareness Month begins, the landscape of preventative healthcare is undergoing a significant strategic shift. Eve Wellness, a pioneer in direct-to-consumer breast cancer screening, announced today that it will open its second Bay Area location in Walnut Creek on October 15. The expansion highlights a growing consumer appetite for accessible, cash-pay medical diagnostics, while simultaneously igniting complex debates among medical professionals regarding care coordination, false positives, and the efficacy of commercial screening models.

Founded in San Francisco in October 2022, Eve Wellness operates on a model that bypasses traditional primary care gatekeepers. For a flat fee of $349—payable via Health Savings Accounts (HSA) or Flexible Spending Accounts (FSA)—patients can walk into a clinic without a doctor’s referral and receive a physician-read, radiation-free 3D ultrasound screening in just 20 minutes. Results are delivered within 48 hours.

"As we expand Eve's locations we continue to work toward our goal of making advanced breast screening easier for women to access," said Brendan Foley, co-founder and president of Eve Wellness. "Over the past four years, our patients have helped us create an experience that is comfortable, efficient and built around their needs. Walnut Creek is the first step in bringing that model to more communities and laying the foundation for Eve to serve women in cities across the country."

Bypassing the Traditional Gatekeeper

The Walnut Creek clinic, situated at 1844 San Miguel Drive near Broadway Plaza, represents more than just a geographic expansion; it is a testament to shifting consumer behavior in healthcare. Frustrated by the friction of traditional referral pathways, long wait times, and the opaque pricing of insurance-based diagnostics, a growing demographic of women is opting to pay out-of-pocket for immediate peace of mind.

However, this direct-to-consumer (DTC) approach introduces unique clinical and financial implications. Traditional breast cancer screening pathways emphasize integration with primary care physicians who can assess overall risk, interpret results within the context of a patient's full medical history, and coordinate subsequent care. By removing the initial gatekeeping function, DTC models shift the burden of care navigation directly onto the patient.

Health economics researchers and oncology clinicians frequently caution that when an indeterminate result arises from a DTC screening, the patient must then navigate the traditional healthcare system to obtain follow-up diagnostics. Diagnostic imaging and, when necessary, biopsies are completed by outside medical providers who make the final diagnosis. This transition can lead to fragmented care, potential delays in treatment, and substantial unexpected bills, as subsequent procedures are often significantly more expensive and may face hurdles with insurance approval lacking a prior primary care referral.

The Dense Breast Dilemma and AI Intervention

The technological foundation of Eve Wellness relies on a combination of established hardware and advanced artificial intelligence. The clinics utilize GE HealthCare's Invenia Automated Breast Ultrasound System (ABUS), which received FDA approval in 2014 as an adjunct to mammography for asymptomatic women with dense breast tissue. Each scan is supported by QView Medical's QVCAD, an FDA-cleared AI software designed to assist radiologists by marking areas of interest on ABUS images.

"For the millions of women with dense breast tissue, mammography alone may not tell the full story. By pairing advanced imaging with AI-powered insights, Eve is giving women greater clarity and confidence while helping clinicians detect potential concerns earlier," said Bob Wang, Founder and CEO of QView Medical.

The clinical community remains divided on the routine use of supplemental ultrasound for asymptomatic women. The American College of Radiology (ACR) considers supplemental ultrasound an option for women with dense breasts, acknowledging that mammography's sensitivity is significantly reduced in dense tissue. Conversely, the U.S. Preventive Services Task Force (USPSTF) maintains that current evidence is insufficient to assess the balance of benefits and harms of supplemental screening using ultrasonography in women identified to have dense breasts on an otherwise negative screening mammogram.

A primary concern among epidemiologists and public health officials is the risk of false positives and overdiagnosis. Supplemental ultrasound inherently leads to an increase in false-positive results, which can cause significant psychological distress and necessitate invasive procedures like biopsies for benign lesions. The financial burden of false positives from breast screening is immense, with some health economic studies estimating the annual cost in the United States to be as high as $4 billion.

Despite these systemic concerns, clinical leadership at the company remains confident in the technology's precision. In a recent interview, Dr. Ian Grady, Medical Director at Eve Wellness, noted the rapid advancement of the underlying algorithms. "The important part of screening at Eve Wellness is the AI software that comes with it. The AI technology has gotten progressively better and better. It's been about three years since I have found a breast cancer that it wasn't able to pick up," Dr. Grady said.

Shifting Demographics: Detecting Cancer Under 40

Perhaps the most striking data to emerge from Eve Wellness’s four years of operation in San Francisco is its detection metrics among younger demographics. Since introducing its direct-to-patient model in October 2022, the company reports having screened more than 4,000 patients. Among those who shared their follow-up results, 41 were diagnosed with cancer.

Statistically, 41 cancers out of 4,000 screenings translates to a cancer detection rate (CDR) of approximately 10.25 per 1,000 screenings. This is notably higher than the typical CDR for mammography alone, which ranges from 2 to 6 per 1,000 women screened. Epidemiologists suggest this elevated rate is likely driven by selection bias; patients seeking out cash-pay supplemental screening often have higher personal concern, known dense breasts, or a family history of the disease.

Most notably, 16 of the 41 diagnosed patients were under the age of 40. Current guidelines from major organizations like the ACR and USPSTF do not recommend routine screening mammography for average-risk women under 40, primarily because the incidence rate is historically low and younger breast tissue is typically denser, making traditional mammograms less effective.

Anisha Malik, one of the clinic's early patients, exemplifies this shifting demographic. "I was 37 when my cancer was found at stage one. I'm incredibly grateful to Eve because this option exists to get an ultrasound, to get the results quickly, to be able to walk in on the same day," Malik said. "Having that ultrasound at Eve was critical to fast-tracking my care. I just wake up with gratitude every day."

Malik’s experience underscores a concerning national trend: the rising incidence of early-onset breast cancer. Recent epidemiological studies show an increase of about 2% per year in women in their 40s. Because standard referral pathways often exclude women under 40 without a documented high-risk profile, DTC models are inadvertently filling a void, capturing cancers in a demographic that is largely underscreened by conventional means.

The Downstream Financial and Equity Impact

As Eve Wellness lays the groundwork for national expansion, the broader implications for healthcare equity cannot be ignored. While $349 may be an accessible price point for middle-to-upper-income consumers seeking supplemental reassurance, cash-pay models inherently risk exacerbating existing health disparities. Individuals from lower socioeconomic backgrounds, who may already face barriers to preventative care, are less likely to have the disposable income or the robust insurance plans required to cover both the initial elective screening and the potentially exorbitant costs of follow-up diagnostic workups.

Furthermore, the familial and strategic ties within the medical technology sector play a crucial role in these expansions. Bob Foley, the father of Eve Wellness founder Brendan Foley, helped guide QVCAD through the FDA regulatory process, and his clinical work on the platform spans more than a decade. This deep-rooted integration of proprietary AI technology with a consumer-facing retail clinic model represents a highly optimized vertical approach to medical diagnostics.

The success of the Walnut Creek location will serve as a critical bellwether for the future of direct-to-consumer medical imaging. As patients increasingly demand the convenience and speed of retail experiences in their healthcare journeys, the tension between consumer empowerment, technological innovation, and established clinical guidelines will only intensify. The healthcare industry is watching closely to see if the DTC model can successfully balance the undeniable benefits of early detection against the systemic risks of fragmented care and overdiagnosis.